Previous close | 194.89 |
Open | 195.28 |
Bid | 186.73 x 800 |
Ask | 201.71 x 800 |
Day's range | 193.73 - 197.13 |
52-week range | 181.22 - 262.00 |
Volume | |
Avg. volume | 566,190 |
Market cap | 9.936B |
Beta (5Y monthly) | 1.34 |
PE ratio (TTM) | 20.50 |
EPS (TTM) | 9.47 |
Earnings date | 01 Aug 2023 - 07 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 249.00 |
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance...
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Mass., May 11, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of 2022.
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
WILMINGTON, Mass., May 01, 2023--Charles River launches Accugenix NGS for bacterial identification and fungal ID; announces partner lab initiative to expand global coverage.
WILMINGTON, Mass., April 11, 2023--Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
WILMINGTON, Mass., April 10, 2023--Charles River highlights the importance of next-generation technologies for oncology drug discovery at AACR 2023.
Key Insights Charles River Laboratories International's estimated fair value is US$212 based on 2 Stage Free Cash Flow...
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
It might be of some concern to shareholders to see the Charles River Laboratories International, Inc. ( NYSE:CRL...
Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
WILMINGTON, Mass., March 13, 2023--Charles River launches Apollo, an intuitive customer platform that provides secure cloud-based access to real-time toxicology study data.
WILMINGTON, Mass., March 13, 2023--Charles River Laboratories To Present At Barclays Global Healthcare Conference
WILMINGTON, Mass., March 09, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade.
Investors who take an interest in Charles River Laboratories International, Inc. ( NYSE:CRL ) should definitely note...
Charles River Laboratories International ( NYSE:CRL ) Full Year 2022 Results Key Financial Results Revenue: US$3.98b...
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Mass., February 22, 2023--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
WILMINGTON, Mass. & CAMBRIDGE, Mass., February 16, 2023--Charles River and Pioneering Medicines enter agreement to deploy Logica to create optimized small molecules that will lead to novel therapies.
WILMINGTON, Mass., February 15, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.